Please provide your email address to receive an email when new articles are posted on . In a real-world retrospective study, researchers found mycophenolate mofetil treatment to be safe and effective ...

Researchers conducted a retrospective analysis of 1435 patients with limited cutaneous SSc from the Italian SPRING registry to assess the purpose of starting mycophenolate mofetil treatment and its ...

A total of 40 solid organ transplant patients underwent colonic biopsy for gastrointestinal symptoms during the study period, of which 32 patients were taking mycophenolate mofetil at the time of ...

New research presented this week at ACR Convergence 2022, the American College of Rheumatology's annual meeting, demonstrated that withholding mycophenolate mofetil for at least 10 days significantly ...

Review the side-effects of Mycophenolate Mofetil as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In ...

We reviewed medical records of patients, 18 years of age or younger, with autoimmune uveitis treated with MMF at our practice from 2005 to 2009. The dose and duration of MMF therapy, inflammation ...

A new large, international study finds that the immunosuppressant drug mycophenolate mofetil is superior to azathioprine, an older immunosuppressant, as a maintenance therapy for lupus nephritis.

Background: The Mycophenolate Steroids Sparing (MYSS) study showed that, when combined with ciclosporin microemulsion, mycophenolate mofetil is not superior to azathioprine in preventing acute ...

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), CellCept for oral suspension, 200 mg/m; of Roche Palo Alto, LLC, it added. The approval bolsters the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Patients treated with mycophenolate mofetil were more ...

♦Contraindicated to pregnant women and patients with known hypersensitivity. It should not be co-administered with Proton Pump Inhibitors (PPIs).

The addition of mycophenolate mofetil (MMF) to a glucocorticoid as a first-line treatment for immune thrombocytopenia (ITP) resulted in greater responses and a reduced risk of relapse or refractory ...